1. Home
  2. SPRO vs LFVN Comparison

SPRO vs LFVN Comparison

Compare SPRO & LFVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

N/A

Current Price

$1.20

Market Cap

71.6M

Sector

Health Care

ML Signal

N/A

Logo Lifevantage Corporation (Delaware)

LFVN

Lifevantage Corporation (Delaware)

N/A

Current Price

$6.47

Market Cap

78.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPRO
LFVN
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.6M
78.0M
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
SPRO
LFVN
Price
$1.20
$6.47
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$11.00
AVG Volume (30 Days)
1.5M
55.8K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
3.56%
EPS Growth
111.81
226.09
EPS
N/A
0.30
Revenue
$66,802,000.00
$203,204,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
$21.73
Revenue Growth
39.24
1.86
52 Week Low
$1.08
$3.90
52 Week High
$3.08
$14.28

Technical Indicators

Market Signals
Indicator
SPRO
LFVN
Relative Strength Index (RSI) 31.16 47.80
Support Level $1.10 $6.05
Resistance Level $1.28 $6.51
Average True Range (ATR) 0.06 0.28
MACD 0.04 -0.00
Stochastic Oscillator 40.00 34.72

Price Performance

Historical Comparison
SPRO
LFVN

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About LFVN Lifevantage Corporation (Delaware)

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.

Share on Social Networks: